Exploring safe dosage levels for new therapeutic compounds.
Official title: IITRI - NON-GLP DOSE RANGE FINDING (DRF) STUDIES-DEC. 2023 #2
Funded at Iit Research Institute · NIH-11212035 · Data updated 2026-11-12
This study is looking for safe dosage levels for new treatments aimed at helping people with neurological conditions, and if you join, you could help test these promising therapies to see how well they work and if they're safe for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Iit Research Institute NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | July 22, 2024 |
| Project end | July 21, 2025 |
| Funding year | 2024 |
| Award (this year) | $201,969 |
| NIH project number | 75N95021D00026-0-759502400004-1 |
| Project ID | NIH-11212035 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation would include individuals with neurological conditions who are seeking new treatment options.
✕Less likely to help
Patients with conditions not addressed by the therapeutic compounds being tested may not receive any benefit from this research.
What this research studies
This research focuses on determining safe dosage ranges for new therapeutic compounds, including small molecules and peptides, through early-stage clinical trials. The study utilizes a network of experienced contract service providers to facilitate the development of these compounds, ensuring they are ready for Phase I clinical testing. Patients may be involved in trials that assess the safety and efficacy of these new treatments, contributing to the advancement of neurological therapies.
Why it matters
Potential benefit: If successful, this research could lead to the development of safer and more effective treatments for neurological disorders.
How similar studies have gone: Previous research has shown success in similar approaches, indicating a promising pathway for developing new neurological therapies.
Where this research is happening
-
Iit Research Institute
Chicago, United States Active
Researchers
- Principal investigator: O'ryan, Michael — Iit Research Institute
- Study coordinator: O'ryan, Michael
Related research
Other NIH-funded projects on the same topics.
-
Developing models to understand infectious diseases.
This study is working on creating models that mimic infectious diseases to help researchers find better treatments, so patients can have more effective options in the future.
-
Developing models to understand infectious diseases.
This study is all about building models that mimic infectious diseases so researchers can learn how they work and find better treatments, which could help patients like you in the future.
-
Investigating the safety of AIT-102 in rats and dogs
This study is looking at how a drug called AIT-102 affects the health of rats and dogs to find out if it can harm specific organs and if those effects can be fixed, which will help make sure it's safe for people in the future.
-
Understanding the safety of new cancer drugs before they are tested in people
This study is looking at the safety of new small molecule drugs that could help treat cancer and other conditions, and it brings together experts to make sure these drugs are safe before they are tested on people, which could lead to better treatments for patients like you.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.